These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 369685)

  • 1. Rubidazone in metastatic breast cancer.
    Legha SS; Benjamin RS; Buzdar AU; Hortobagyi GN; Blumenschein GR
    Cancer Treat Rep; 1979 Jan; 63(1):135-6. PubMed ID: 369685
    [No Abstract]   [Full Text] [Related]  

  • 2. Idarubicin in advanced breast cancer: a phase II study.
    Lionetto R; Pronzato P; Conte PF; Sertoli MR; Amoroso D; Rosso R
    Cancer Treat Rep; 1986 Dec; 70(12):1439-40. PubMed ID: 3466694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of rubidazone and adriamycin in women with advanced breast cancer.
    Ingle JN; Ahmann DL; O'Fallon JR; Bisel HF; Rubin J; Kvols LK; Giuliani ER
    Cancer Treat Rep; 1979; 63(11-12):1701-5. PubMed ID: 526908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial of rubidazone in solid tumors and malignant lymphomas.
    Skovsgaard T; Hansen HH; Mouridsen HT; Nissen NI; Pedersen-Bjergaard J
    Cancer Treat Rep; 1978 Jul; 62(7):1053-8. PubMed ID: 356967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new anthracycline 4-demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. A pilot study.
    Martoni A; Pacciarini MA; Pannuti F
    Drugs Exp Clin Res; 1985; 11(2):127-31. PubMed ID: 3915281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase II study of 4-demethoxydaunorubicin in metastatic breast neoplasms].
    Lionetto R; Ardizzoni A; Repetto L; Pronzato P; Sertoli MR; Rosso R
    G Ital Chemioter; 1985; 32(1):59-60. PubMed ID: 3868637
    [No Abstract]   [Full Text] [Related]  

  • 7. [Results of a clinical study of carminomycin in primary disseminated forms, recurrences and metastases of breast cancer].
    Danova LA; Trishkina EA; Gershanovich ML
    Vopr Onkol; 1983; 29(2):46-51. PubMed ID: 6340345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of orally administered idarubicin in patients with advanced breast cancer.
    Casper ES; Raymond V; Hakes TB; Currie VE; Kaufman RJ
    Cancer Treat Rep; 1987 Dec; 71(12):1289-90. PubMed ID: 3480045
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase-II trial of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
    Wander HE; Meyer D; Schuff-Werner P; Nagel GA
    Onkologie; 1986 Aug; 9(4):236-8. PubMed ID: 3531951
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II evaluation of rubidazone (NSC-164011) in advanced carcinoma of the breast. A Southwest Oncology Group study.
    Smith FE; Gad-el-Mawla N; Tranum B; Baker LH; Panettiere FJ; Athens JW; Foulkes M
    Invest New Drugs; 1983; 1(4):315-9. PubMed ID: 6678878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials referral resource. Clinical trials with paclitaxel in metastatic breast cancer.
    Cheson BD; Abrams JS; Arbuck SG; Phillips PH
    Oncology (Williston Park); 1994 Jan; 8(1):72-3, 76-7. PubMed ID: 7907222
    [No Abstract]   [Full Text] [Related]  

  • 12. Esorubicin in refractory metastatic carcinoma of the breast: a Northern California Oncology Group Study.
    Carlson RW; Billingham ME; Kohler M; Johnson FD; Doroshow JH; Torti FM
    Cancer Treat Rep; 1987 Apr; 71(4):427-8. PubMed ID: 3548961
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
    Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte PF
    Bone Marrow Transplant; 2003 Feb; 31(4):275-80. PubMed ID: 12621462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of i.v. menogaril in patients with malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group Study.
    McCulloch PB; Eisenhauer EA; Shibata HR; Young VP
    Cancer Treat Rep; 1987; 71(7-8):771-2. PubMed ID: 2955887
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients.
    Bastholt L; Dalmark M
    Cancer Treat Rep; 1987 May; 71(5):451-4. PubMed ID: 3471329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New cytotoxic drugs for breast cancer and their clinical evaluation.
    Carter SK
    Eur J Cancer (1965); 1980; Suppl 1():265-70. PubMed ID: 6459235
    [No Abstract]   [Full Text] [Related]  

  • 17. [Rubidazone (22 050 RP): clinical study. Phase II trial in solid tumors and lymphomas (author's transl)].
    Chauvergne J; Cappelaere P; Carton M; Gary-Bobo J; Klein T
    Bull Cancer; 1978; 65(1):19-24. PubMed ID: 667371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy of primary and metastasizing breast cancer].
    Hofmann V; Martz G
    Gynakol Rundsch; 1984; 24 Suppl 1():78-86. PubMed ID: 6394442
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II evaluation of oral idarubicin (4-demethoxydaunorubicin) in patients with disseminated malignant melanoma.
    Lopez M; Di Lauro L; Papaldo P; Ganzina F; Di Pietro N; Lazzaro B
    Cancer Treat Rep; 1986 Jul; 70(7):911-2. PubMed ID: 3459575
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized clinical trials in breast cancer: a tabular summary. Part 1: Primary breast cancer.
    Conrad B; Kieser R
    Arch Geschwulstforsch; 1986; 56(3):211-36. PubMed ID: 3524501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.